Pharmaceuticals business segment growth likely to be healthy Recent long term contracts in the radiopharma business as well as approval for Rubyfill in the US will strengthen the speciality sub-segment growth, which is likely to grow at ~20.5% CAGR in FY18-21E to | 3856 crore on the back of strong growth in the radiopharma business and consolidation of pharmacy business. CDMO business is witnessing strong traction on the back of robust order book and incremental realisation in API segment. Generic business is also registering decent growth on the back of base...